Frank Beurskens, PhDPrincipal Scientist at Genmab
Dr. Frank Beurskens works at Genmab since 2002. He is interested in how antibodies work and how they can boost the immune system of patients. He discovered that antibodies act together as a team after binding to the target at the cell surface. This knowledge lead to the discovery of the HexaBody® and HexElect® technologies, which he co-developed. He currently leads Genmab’s Antibody Format Translation efforts, aimed at translating novel therapeutic antibody platform technologies into potential immune-therapeutics.